2023
DOI: 10.3390/ijms24021094
|View full text |Cite
|
Sign up to set email alerts
|

PLVAP as an Early Marker of Glomerular Endothelial Damage in Mice with Diabetic Kidney Disease

Abstract: Plasmalemma vesicle-associated protein (PLVAP) is the main component of endothelial diaphragms in fenestrae, caveolae, and transendothelial channels. PLVAP is expressed in the adult kidney glomerulus upon injury. Glomerular endothelial injury is associated with progressive loss of kidney function in diabetic kidney disease (DKD). This study aimed to investigate whether PLVAP could serve as a marker for glomerular endothelial damage in DKD. Glomerular PLVAP expression was analyzed in different mouse models of D… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 47 publications
0
2
0
Order By: Relevance
“…In the context of DKD, both endothelial dysfunction and inflammation are recognized as contributors to disease progression [ 55 58 ]. However, the specific relationship between endothelial inflammation and glycocalyx shedding in DKD remains unclear.…”
Section: Discussionmentioning
confidence: 99%
“…In the context of DKD, both endothelial dysfunction and inflammation are recognized as contributors to disease progression [ 55 58 ]. However, the specific relationship between endothelial inflammation and glycocalyx shedding in DKD remains unclear.…”
Section: Discussionmentioning
confidence: 99%
“…The PLVAP protein is the main component of endothelial diaphragms in fenestrae, caveolae, and transendothelial channels, shown in previous studies to be associated with DKD and HCC. On the one hand, PLVAP can be used as an early marker of glomerular endothelial injury with DKD in mice ( 44 ), and do increase in glomeruli of human diabetic patients ( 45 ). On the other hand, PLVAP was identified as a gene expressed explicitly in HCC vascular endothelial cells ( 46 ), and has been investigated as a therapeutic target in HCC ( 46 ), perhaps based on its ability to alter the immunosuppressive microenvironment ( 47 ).…”
Section: Discussionmentioning
confidence: 99%